Next-Generation Nano-, Capillary- and Micro-Flow LC Systems Enhance Productivity and Performance

Next-Generation Nano-, Capillary- and Micro-Flow LC Systems Enhance Productivity and Performance Thermo Scientific Vanquish Neo UHPLC System and Thermo Scientific PepMap Neo Columns enable consistent, high-quality results in high-sensitivity LC-MS workflows GERMERING, Germany, Sept. 8, 2021 /PRNewswire/ — Principal investigators, laboratories, and proteomics researchers in academia, biopharma and contract research organizations can now benefit from an... Read more

New Mass Spectrometry Portfolio Leverages Enhanced Hardware and Software to Advance Quantitative Analysis

New Mass Spectrometry Portfolio Leverages Enhanced Hardware and Software to Advance Quantitative Analysis Thermo Scientific TSQ Plus triple quadrupole mass spectrometer portfolio meets productivity demands through improved speed and sensitivity SAN JOSE, Calif., Sept. 8, 2021 /PRNewswire/ — Lab managers, technology leaders and principal scientists in pharmaceutical, food and environmental laboratories can now benefit from accelerated... Read more

Thermo Fisher Scientific to Further Expand Global Network of Single-Use Technology Manufacturing Sites

Thermo Fisher Scientific to Further Expand Global Network of Single-Use Technology Manufacturing Sites Nashville site will deliver on strategy to enable reliable supply of critical materials used to produce new biologics and vaccines WALTHAM, Mass., Sept. 8, 2021 /PRNewswire/ — Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced plans to... Read more

Illumina Partners with Merck to Develop and Commercialize Companion Diagnostic and Research Tests for Use in Identifying Specific Cancer Mutations

Sep 7, 2021 SAN DIEGO, Sept. 7, 2021 /PRNewswire/ — Illumina, Inc. (NASDAQ: ILMN) and Merck (known as MSD outside the United States and Canada) today announced a partnership to develop and commercialize tests that identify genetic mutations used in the assessment of homologous recombination deficiency (HRD). Patients whose tumors are HRD-positive may be eligible for... Read more

FOSS proudly announces a new milestone in near infrared NIR analysis, the NIRS™ DS3 analyser.

Innovative analysis helps to tackle volatile conditions in food and feed production By FOSS Tuesday, September 7, 2021 Today’s technology tackles the threats and troubles of tomorrow. As supply chains and regulations are becoming more complex, the need for transparency in terms of data and processes is influencing quality management in food and feed production.... Read more

Illumina Acquires GRAIL to Accelerate Patient Access to Life-Saving Multi-Cancer Early-Detection Test

Sep 7, 2021 SAN DIEGO, Sept. 7, 2021 /PRNewswire/ — Illumina, Inc. (NASDAQ: ILMN) and Merck (known as MSD outside the United States and Canada) today announced a partnership to develop and commercialize tests that identify genetic mutations used in the assessment of homologous recombination deficiency (HRD). Patients whose tumors are HRD-positive may be eligible for... Read more

ENPICOM introduces a powerful liability prediction solution to de-risk antibody development

The IGX Platform empowers researchers to accurately predict exposed liabilities for thousands of sequences at the same time using high-throughput structural modeling Caption:The IGX Platform to select better antibodies. To download image, please click here. ‘s-Hertogenbosch, The Netherlands – September 7, 2021 – Life Science Newswire – ENPICOM, an innovative bioinformatics software company, announced today at the Biologics UK conference new IGX... Read more

Speeding up Breast Cancer Diagnosis in Egypt: GE Healthcare, Gustave Roussy and the Egypt Ministry of Health Partner to Create Rapid Breast Cancer Diagnosis Clinics

Cairo, Egypt and Villejuif & Buc, France – September 7, 2021 – GE Healthcare, Gustave Roussy and the Egypt Ministry of Health (MOH) signed a preliminary agreement leveraging Gustave Roussy’s One Stop Breast Cancer diagnostics program to increase the speed and the accuracy of breast cancer diagnosis in Egypt. Breast cancer is the most common... Read more

Roche to present data from industry leading portfolio at ESMO 2021 showing significant progress in early stage and uncommon cancers

First data to be presented from the phase II coopERA Breast Cancer study evaluating neoadjuvant giredestrant treatment for oestrogen receptor (ER)-positive, HER2-negative breast cancer New data from the phase III IMpower010 study provide further insights into the role of Tecentriq® (atezolizumab) in early-stage non-small cell lung cancer (NSCLC) Genomic data from the phase II CUPISCO... Read more

The Intricate Network of Immune Cells Revealed by Multiplex Tissue Microscopy

When our immune systems identify invaders – such as parasites, bacteria or viruses – it can spark inflammation, which brings fluid and immune cells to the area of infection. While this can be very effective in battling infection, it also has collateral damage on nearby healthy tissues. In our daily lives, just by eating or... Read more